Urological Cancer 2021

Cancer of the urological sphere is a disease continuously increasing in numbers in the statistics of tumor malignancies in Western countries. Although this fact is mainly due to the contemporary increase of life expectancy of the people in these geographic areas, many other factors do contribute as...

Full description

Saved in:
Bibliographic Details
TeilnehmendeR:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (328 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993544476204498
ctrlnum (CKB)5720000000008448
(oapen)https://directory.doabooks.org/handle/20.500.12854/84579
(EXLCZ)995720000000008448
collection bib_alma
record_format marc
spelling Urological Cancer 2021
MDPI - Multidisciplinary Digital Publishing Institute 2022
1 electronic resource (328 pages)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Cancer of the urological sphere is a disease continuously increasing in numbers in the statistics of tumor malignancies in Western countries. Although this fact is mainly due to the contemporary increase of life expectancy of the people in these geographic areas, many other factors do contribute as well to this growth. Urological cancer is a complex and varied disease of different organs and mainly affects the male population. In fact, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males in most statistics. The female population, however, has also increasingly found itself affected by renal and bladder cancer in the last decade. Considering these altogether, urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light into the complexity of this field and will consider all useful and appropriate contributions that scientists and clinicians may provide to improve urological cancer knowledge for patients’ benefit. The precise identification of the molecular routes involved, the diagnostic pathological criteria in the grey zones, the dilemma of T1G3 management, and the possible treatment options between superficial, nonmuscle-invasive and muscle-invasive diseases will be particularly welcomed in this Issue.
English
Research.
Chemistry.
bladder cancer
radiotherapy
radiosensitisation
molecular subtypes
preclinical studies
bladder cancer cell lines
latent cancer
prostate cancer
autopsy
prognostic index
prediction model
mortality
screening trial
renal cell carcinoma
PD-1
PD-L1
biomarkers
immune checkpoint inhibitors
prostatic neoplasms
positron-emission tomography
decision making
tumor thrombus
metastasectomy
postoperative complications
oncological outcomes
radical cystectomy
AHNAK2
prognosis
dog
comparative oncology
inflammation
prostatic atrophy
preneoplastic lesion
biomarker
urine
machine learning
TRIPOD
liquid biopsy
glutaminase
immunohistochemistry
in situ methods
prostate
PSMA-RLT
177Lu-PSMA
PSA
mCRPC
urinary bladder neoplasms
Bacillus Calmette-Guérin (BCG)
immunotherapy
divergent differentiation
variant morphology
survival
stereotactic body radiotherapy
frail patients
cancer
metastasis
genomic analysis
microenvironment
tumor ecology
game theory
fluorescence confocal microscopy
prostate biopsy
ablation margins
focal therapy
sphingosine 1-phosphate receptor 1
bladder carcinoma
cell migration
epithelial-mesenchymal transition
FTY-720
OIP5
papillary renal cell carcinoma
PLK1
tumorigenesis
therapy
image-guided
magnetic resonance imaging
ultrasonography
biopsy
abiraterone
enzalutamide
docetaxel
novel hormonal therapies
comparative effectiveness
real-world treatment pattern
metastatic prostate cancer
epiplakin
diagnosis
advanced urothelial carcinoma
immune checkpoint inhibitor
prognostic
tumour mutational board
genomic signatures
ctDNA
inflammatory indices
urothelial carcinoma
frailty
prognostic factor
psoas muscle
Hounsfield units
3-0365-3048-7
3-0365-3049-5
Manini, Claudia. editor.
López, José I., editor.
language English
format eBook
author2 Manini, Claudia.
López, José I.,
author_facet Manini, Claudia.
López, José I.,
author2_variant c m cm
j i l ji jil
author2_role TeilnehmendeR
TeilnehmendeR
title Urological Cancer 2021
spellingShingle Urological Cancer 2021
title_full Urological Cancer 2021
title_fullStr Urological Cancer 2021
title_full_unstemmed Urological Cancer 2021
title_auth Urological Cancer 2021
title_new Urological Cancer 2021
title_sort urological cancer 2021
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2022
physical 1 electronic resource (328 pages)
isbn 3-0365-3048-7
3-0365-3049-5
illustrated Not Illustrated
work_keys_str_mv AT maniniclaudia urologicalcancer2021
AT lopezjosei urologicalcancer2021
status_str n
ids_txt_mv (CKB)5720000000008448
(oapen)https://directory.doabooks.org/handle/20.500.12854/84579
(EXLCZ)995720000000008448
carrierType_str_mv cr
is_hierarchy_title Urological Cancer 2021
author2_original_writing_str_mv noLinkedField
noLinkedField
_version_ 1796652272587898880
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05477nam-a2201489z--4500</leader><controlfield tag="001">993544476204498</controlfield><controlfield tag="005">20231220174817.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202206s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5720000000008448</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/84579</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995720000000008448</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Urological Cancer 2021</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (328 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cancer of the urological sphere is a disease continuously increasing in numbers in the statistics of tumor malignancies in Western countries. Although this fact is mainly due to the contemporary increase of life expectancy of the people in these geographic areas, many other factors do contribute as well to this growth. Urological cancer is a complex and varied disease of different organs and mainly affects the male population. In fact, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males in most statistics. The female population, however, has also increasingly found itself affected by renal and bladder cancer in the last decade. Considering these altogether, urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light into the complexity of this field and will consider all useful and appropriate contributions that scientists and clinicians may provide to improve urological cancer knowledge for patients’ benefit. The precise identification of the molecular routes involved, the diagnostic pathological criteria in the grey zones, the dilemma of T1G3 management, and the possible treatment options between superficial, nonmuscle-invasive and muscle-invasive diseases will be particularly welcomed in this Issue.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Research.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Chemistry.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiosensitisation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular subtypes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">preclinical studies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder cancer cell lines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">latent cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic index</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prediction model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mortality</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">screening trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostatic neoplasms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">positron-emission tomography</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">decision making</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor thrombus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">postoperative complications</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncological outcomes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radical cystectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AHNAK2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dog</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">comparative oncology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostatic atrophy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">preneoplastic lesion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">machine learning</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TRIPOD</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liquid biopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glutaminase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in situ methods</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PSMA-RLT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">177Lu-PSMA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PSA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mCRPC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urinary bladder neoplasms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bacillus Calmette-Guérin (BCG)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">divergent differentiation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">variant morphology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stereotactic body radiotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">frail patients</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomic analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor ecology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">game theory</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fluorescence confocal microscopy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate biopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ablation margins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">focal therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sphingosine 1-phosphate receptor 1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell migration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epithelial-mesenchymal transition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">FTY-720</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">OIP5</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">papillary renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PLK1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumorigenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">image-guided</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">magnetic resonance imaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ultrasonography</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">abiraterone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">enzalutamide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">docetaxel</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">novel hormonal therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">comparative effectiveness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">real-world treatment pattern</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastatic prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epiplakin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">advanced urothelial carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumour mutational board</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomic signatures</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ctDNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammatory indices</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urothelial carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">frailty</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic factor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">psoas muscle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Hounsfield units</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3048-7</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3049-5</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manini, Claudia.</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">López, José I.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-22 01:58:10 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-07-02 22:45:44 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337635440004498&amp;Force_direct=true</subfield><subfield code="Z">5337635440004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337635440004498</subfield></datafield></record></collection>